JP2011511076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011511076A5 JP2011511076A5 JP2010545895A JP2010545895A JP2011511076A5 JP 2011511076 A5 JP2011511076 A5 JP 2011511076A5 JP 2010545895 A JP2010545895 A JP 2010545895A JP 2010545895 A JP2010545895 A JP 2010545895A JP 2011511076 A5 JP2011511076 A5 JP 2011511076A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- peptidomimetic macrocycle
- amino acid
- polypeptide
- linking agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 claims 12
- 239000000816 peptidomimetic Substances 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 10
- 239000003431 cross linking reagent Substances 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 239000004971 Cross linker Substances 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 238000005462 in vivo assay Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 125000005842 heteroatoms Chemical group 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (27)
- 障害の治療を必要とするヒト患者における障害を治療するための医薬の製造におけるペプチド模倣大環状分子の使用であって、
a)ポリペプチドの2つのアミノ酸残基の間に架橋剤を導入することによって治療用ペプチド模倣大環状分子を調製する工程、
b)インビボアッセイにおいて最小の抗体応答についてペプチド模倣大環状分子を試験する工程、および
c)対応する非架橋ポリペプチドと比較して前記ペプチド模倣大環状分子が減少した免疫原性の応答を有する場合に、ペプチド模倣大環状分子を医薬の製造において使用する工程
を含む使用。 - 前記減少した免疫原性の応答が、インビボアッセイにおいて最小の抗体応答として証明される、請求項1に記載の使用。
- ペプチド模倣大環状分子がヘリックスを含む、請求項1に記載の使用。
- ペプチド模倣大環状分子がα−ヘリックスを含む、請求項1に記載の使用。
- 障害が癌である、請求項1に記載の使用。
- 障害が代謝障害である、請求項1に記載の使用。
- ペプチド模倣大環状分子がBH3ドメインを含む、請求項1に記載の使用。
- 前記ペプチド模倣大環状分子におけるα−炭素原子が、式R−の独立した置換基でさらに置換され、R−は、非置換もしくハロ−で置換された、アルキル、アルケニル、アルキニル、アリールアルキル、シクロアルキルアルキル、ヘテロアルキル、またはヘテロシクロアルキルである、請求項1に記載の使用。
- 架橋剤が接続するα−炭素原子が、式R−の置換基でさらに置換され、R−は、非置換もしくはハロ−で置換された、アルキル、アルケニル、アルキニル、アリールアルキル、シクロアルキルアルキル、ヘテロアルキル、またはヘテロシクロアルキルである、請求項8に記載の使用。
- 架橋剤が接続する2つのα−炭素原子が、式R−の独立した置換基でさらに置換され、R−は、非置換もしくはハロ−で置換された、アルキル、アルケニル、アルキニル、アリールアルキル、シクロアルキルアルキル、ヘテロアルキル、またはヘテロシクロアルキルである、請求項9に記載の使用。
- R−がアルキルである、請求項8に記載の使用。
- 架橋剤が2つのα−炭素原子を連結する、請求項1に記載の使用。
- 架橋剤が連続した炭素−炭素結合から形成される、請求項1に記載の使用。
- 架橋剤が連続した約9個の結合を含有する、請求項1に記載の使用。
- 架橋剤が連続した約12個の結合を含有する、請求項1に記載の使用。
- 架橋剤が少なくとも約6個の炭素原子を含む、請求項1に記載の使用。
- 架橋剤が少なくとも約9個の炭素原子を含む、請求項1に記載の使用。
- ペプチド模倣大環状分子が細胞透過性である、請求項1に記載の使用。
- 架橋剤の長さが、α−ヘリックスのターン当たり約5Å〜約9Åである、請求項4に記載の使用。
- ペプチド模倣大環状分子がBIDポリペプチドである、請求項1に記載の使用。
- BIDポリペプチドが、配列DIIRNIARHLA*VGD*NleDRSI(配列番号2)と約60%超同一であり、*はテザーアミノ酸であり、Nleはノルロイシンである、請求項20に記載の使用。
- BIDポリペプチドが、配列DIIRNIARHLA*VGD*NleDRSI(配列番号2)と約80%超同一であり、*はテザーアミノ酸であり、Nleはノルロイシンである、請求項20に記載の使用。
- BIDポリペプチドが、配列DIIRNIARHLA*VGD*NleDRSI(配列番号2)と約95%超同一であり、*はテザーアミノ酸であり、Nleはノルロイシンである、請求項20に記載の方法。
- ペプチド模倣大環状分子がBIMポリペプチドである、請求項1に記載の使用。
- BIMポリペプチドが、アミノ酸配列IWIAQELR*IGD*FNAYYARR(配列番号1)と約60%超同一であり、*はテザーアミノ酸である、請求項24に記載の使用。
- BIMポリペプチドが、アミノ酸配列IWIAQELR*IGD*FNAYYARR(配列番号1)と約80%超同一であり、*は、テザーアミノ酸である、請求項24に記載の使用。
- BIMポリペプチドが、アミノ酸配列IWIAQELR*IGD*FNAYYARR(配列番号1)と約95%超同一であり、*はテザーアミノ酸である、請求項24に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2732608P | 2008-02-08 | 2008-02-08 | |
US12038008P | 2008-12-05 | 2008-12-05 | |
PCT/US2009/000837 WO2009099677A2 (en) | 2008-02-08 | 2009-02-09 | Therapeutic peptidomimetic macrocycles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014244169A Division JP2015078208A (ja) | 2008-02-08 | 2014-12-02 | 治療用ペプチド模倣大環状分子 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011511076A JP2011511076A (ja) | 2011-04-07 |
JP2011511076A5 true JP2011511076A5 (ja) | 2012-03-29 |
Family
ID=40952614
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010545895A Pending JP2011511076A (ja) | 2008-02-08 | 2009-02-09 | 治療用ペプチド模倣大環状分子 |
JP2014244169A Pending JP2015078208A (ja) | 2008-02-08 | 2014-12-02 | 治療用ペプチド模倣大環状分子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014244169A Pending JP2015078208A (ja) | 2008-02-08 | 2014-12-02 | 治療用ペプチド模倣大環状分子 |
Country Status (12)
Country | Link |
---|---|
US (4) | US20090275519A1 (ja) |
EP (2) | EP2926827A3 (ja) |
JP (2) | JP2011511076A (ja) |
KR (1) | KR20100126361A (ja) |
CN (2) | CN101980718A (ja) |
BR (1) | BRPI0907754A2 (ja) |
CA (1) | CA2714251C (ja) |
DE (1) | DE112009000300T5 (ja) |
GB (1) | GB2471588A (ja) |
IL (2) | IL207421A0 (ja) |
WO (1) | WO2009099677A2 (ja) |
ZA (1) | ZA201005741B (ja) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008061192A2 (en) | 2006-11-15 | 2008-05-22 | Dana-Farber Cancer Institute, Inc. | Stabilized maml peptides and uses thereof |
US7981998B2 (en) * | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
EP2094721B1 (en) * | 2006-12-14 | 2018-02-14 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
CA2939778C (en) | 2007-01-31 | 2019-01-29 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
ES2648687T3 (es) | 2007-02-23 | 2018-01-05 | Aileron Therapeutics, Inc. | Péptidos macrocíclicos unidos a triazol |
CN101730708B (zh) | 2007-03-28 | 2013-09-18 | 哈佛大学校长及研究员协会 | 缝合多肽 |
KR20100126361A (ko) | 2008-02-08 | 2010-12-01 | 에일러론 테라퓨틱스 인코포레이티드 | 치료용 펩티드유사 거대고리 |
WO2010034034A1 (en) * | 2008-09-22 | 2010-03-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
EP2352507A4 (en) | 2008-11-24 | 2012-04-25 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES |
AU2010204648B2 (en) | 2009-01-14 | 2016-09-01 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CA2774973A1 (en) * | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CA2777700A1 (en) * | 2009-10-14 | 2011-04-21 | Aileron Therapeutics, Inc. | Improved peptidomimetic macrocycles |
GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
JP2013528174A (ja) | 2010-05-28 | 2013-07-08 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | オリゴベンズアミド化合物およびそれらの使用 |
SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
US9169295B2 (en) | 2010-10-13 | 2015-10-27 | Bristol-Myers Squibb Company | Macrocycles and macrocycle stabilized peptides |
JP2014502152A (ja) | 2010-11-12 | 2014-01-30 | ダナ ファーバー キャンサー インスティテュート,インコーポレイテッド | 癌の治療及び診断 |
WO2012083078A2 (en) | 2010-12-15 | 2012-06-21 | The Research Foundation Of State University Of New York | Croos-linked peptides and proteins, methods of making same, and uses thereof |
WO2013059525A1 (en) | 2011-10-18 | 2013-04-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocyles |
US8835493B2 (en) | 2011-11-23 | 2014-09-16 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
WO2013078277A1 (en) | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
US9464125B2 (en) * | 2012-02-03 | 2016-10-11 | The Trustees Of Princeton University | Engineered potent cytotoxic stapled BH3 peptides |
CN108912211A (zh) | 2012-02-15 | 2018-11-30 | 爱勒让治疗公司 | 三唑交联的和硫醚交联的拟肽大环化合物 |
SG11201404648PA (en) | 2012-02-15 | 2014-09-26 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
SG10201805807PA (en) * | 2012-06-26 | 2018-08-30 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
EP2914256B1 (en) | 2012-11-01 | 2019-07-31 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
US10286078B2 (en) | 2013-09-13 | 2019-05-14 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
CN106456589B (zh) | 2013-12-18 | 2020-07-07 | 斯克利普斯研究所 | 修饰的治疗剂、订合的肽脂质缀合物及其组合物 |
JP6642887B2 (ja) * | 2014-04-02 | 2020-02-12 | ユニバーシティー オブ ロチェスター | アルファヘリックスを模倣した大環状ペプチドミメティック |
WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
BR112017005736A2 (pt) * | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e formulações dos mesmos |
AU2016232833A1 (en) * | 2015-03-18 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Selective Mcl-1 binding peptides |
US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
WO2017053391A1 (en) | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
PL3368544T3 (pl) | 2015-10-27 | 2020-11-16 | F. Hoffmann-La Roche Ag | Peptydowe związki makrocykliczne przeciwko Acinetobacter baumannii |
WO2017075349A2 (en) * | 2015-10-30 | 2017-05-04 | Massachusetts Institute Of Technology | Selective mcl-1 binding peptides |
CN116731101A (zh) | 2016-06-01 | 2023-09-12 | 雅斯娜 | 用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物 |
US11198715B2 (en) | 2016-07-22 | 2021-12-14 | Massachusetts Institute Of Technology | Selective Bfl-1 peptides |
EP3388444A1 (en) | 2017-04-10 | 2018-10-17 | F. Hoffmann-La Roche AG | Anti-bacterial peptide macrocycles and use thereof |
WO2018232062A1 (en) | 2017-06-15 | 2018-12-20 | University Of Washington | Macrocyclic polypeptides |
US11505573B2 (en) | 2018-03-28 | 2022-11-22 | Hoffmann-La Roche Inc. | Peptide macrocycles against Acinetobacter baumannii |
US11819532B2 (en) | 2018-04-23 | 2023-11-21 | Hoffmann-La Roche Inc. | Peptide macrocycles against Acinetobacter baumannii |
US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
US11286299B2 (en) | 2018-09-17 | 2022-03-29 | Massachusetts Institute Of Technology | Peptides selective for Bcl-2 family proteins |
AU2020241429A1 (en) * | 2019-03-15 | 2021-10-07 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
WO2023069332A1 (en) * | 2021-10-22 | 2023-04-27 | Merck Sharp & Dohme Llc | Cell permeable macrocyclic peptides useful for eif4e cap-binding site inhibition |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US753819A (en) * | 1903-04-08 | 1904-03-01 | George Jones Atkins | Electrode. |
US5712418A (en) * | 1989-10-23 | 1998-01-27 | Research Corporation Technologies, Inc. | Synthesis and use of amino acid fluorides as peptide coupling reagents |
DE69118826T2 (de) | 1990-11-27 | 1996-11-14 | Fuji Photo Film Co Ltd | Propenamidderivate, deren Polymere, Copolymere und deren Verwendung |
US5364851A (en) | 1991-06-14 | 1994-11-15 | International Synthecon, Llc | Conformationally restricted biologically active peptides, methods for their production and uses thereof |
EP1251135A3 (en) * | 1992-04-03 | 2004-01-02 | California Institute Of Technology | High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof |
US5411860A (en) * | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
US5622852A (en) * | 1994-10-31 | 1997-04-22 | Washington University | Bcl-x/Bcl-2 associated cell death regulator |
US5824483A (en) | 1994-05-18 | 1998-10-20 | Pence Inc. | Conformationally-restricted combinatiorial library composition and method |
US6407059B1 (en) * | 1994-06-08 | 2002-06-18 | Peptor Limited | Conformationally constrained backbone cyclized peptide analogs |
IL109943A (en) * | 1994-06-08 | 2006-08-01 | Develogen Israel Ltd | Conformationally constrained backbone cyclized peptide analogs |
US7553929B2 (en) * | 1994-06-13 | 2009-06-30 | Vanderbilt University | Cell permeable peptides for inhibition of inflammatory reactions and methods of use |
US5807746A (en) | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
US5770377A (en) * | 1994-07-20 | 1998-06-23 | University Of Dundee | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
US5672584A (en) * | 1995-04-25 | 1997-09-30 | The University Of Kansas | Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
US5811515A (en) | 1995-06-12 | 1998-09-22 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis |
WO1997026278A1 (en) * | 1996-01-18 | 1997-07-24 | Steeno Research Group A/S | Synthetic il-10 analogues |
US5663316A (en) * | 1996-06-18 | 1997-09-02 | Clontech Laboratories, Inc. | BBC6 gene for regulation of cell death |
US7083983B2 (en) * | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
US5955593A (en) * | 1996-09-09 | 1999-09-21 | Washington University | BH3 interacting domain death agonist |
US5965703A (en) * | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
US5856445A (en) * | 1996-10-18 | 1999-01-05 | Washington University | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator |
US6271198B1 (en) * | 1996-11-06 | 2001-08-07 | Genentech, Inc. | Constrained helical peptides and methods of making same |
EP1015578A4 (en) * | 1997-09-17 | 2004-12-01 | Walker And Eliza Hall Inst Of | THERAPEUTIC MOLECULES |
US6165732A (en) | 1997-10-14 | 2000-12-26 | Washington University | Method for identifying apoptosis modulating compounds |
US6030997A (en) * | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
JP2002511483A (ja) | 1998-04-15 | 2002-04-16 | アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド | 樹脂結合環状ペプチドの製造方法 |
US6326354B1 (en) * | 1998-08-19 | 2001-12-04 | Washington University | Modulation of apoptosis with bid |
RU2213098C2 (ru) * | 1999-03-29 | 2003-09-27 | Дзе Проктер Энд Гэмбл Компани | Лиганды меланокортиновых рецепторов |
EP1210098A1 (en) * | 1999-04-07 | 2002-06-05 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
US6713280B1 (en) | 1999-04-07 | 2004-03-30 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
US7192713B1 (en) * | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US6495674B1 (en) | 2000-02-25 | 2002-12-17 | The Salk Institute For Biological Studies | Evectins and their use |
WO2002013833A2 (en) * | 2000-08-16 | 2002-02-21 | Georgetown University Medical Center | SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2 |
WO2002064790A2 (en) | 2000-12-19 | 2002-08-22 | The Johns Hopkins University | Jfy1 protein induces rapid apoptosis |
US6815426B2 (en) * | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
CA2471719A1 (en) * | 2001-12-31 | 2003-07-17 | Dana-Farber Cancer Institute, Inc. | Method of treating apoptosis and compositions thereof |
SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
US20040171809A1 (en) * | 2002-09-09 | 2004-09-02 | Korsmeyer Stanley J. | BH3 peptides and method of use thereof |
US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
AU2004204942A1 (en) * | 2003-01-08 | 2004-07-29 | Xencor, Inc | Novel proteins with altered immunogenicity |
EP1673386A2 (en) | 2003-10-16 | 2006-06-28 | AplaGen GmbH | Stabilized alpha-helical peptides |
CA2544223C (en) * | 2003-11-05 | 2017-03-07 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
US8193310B2 (en) | 2004-03-19 | 2012-06-05 | The University Of Queensland | Alpha helical mimics, their uses and methods for their production |
WO2005118620A2 (en) * | 2004-05-27 | 2005-12-15 | New York University | Methods for preparing internally constraied peptides and peptidomimetics |
WO2005118634A2 (en) | 2004-06-04 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Helical peptidomimetics with enhanced activity against beta-amyloid production |
US7842815B2 (en) * | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
MXPA06014754A (es) * | 2004-06-17 | 2007-06-22 | Infinity Pharmaceuticals Inc | Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace. |
WO2006103666A2 (en) | 2005-03-28 | 2006-10-05 | Yeda Research And Development Co. Ltd. | Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis |
US7538190B2 (en) | 2006-02-17 | 2009-05-26 | Polychip Pharmaceuticals Pty Ltd | Methods for the synthesis of two or more dicarba bridges in organic compounds |
US7745573B2 (en) * | 2006-02-17 | 2010-06-29 | Polychip Pharmaceuticals Pty Ltd. | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides |
US7981998B2 (en) * | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
EP2094721B1 (en) * | 2006-12-14 | 2018-02-14 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
ES2648687T3 (es) * | 2007-02-23 | 2018-01-05 | Aileron Therapeutics, Inc. | Péptidos macrocíclicos unidos a triazol |
CN101730708B (zh) * | 2007-03-28 | 2013-09-18 | 哈佛大学校长及研究员协会 | 缝合多肽 |
US10716828B2 (en) * | 2007-05-02 | 2020-07-21 | Dana-Farber Cancer Institute, Inc. | Methods of modulating cellular homeostatic pathways and cellular survival |
WO2009042237A2 (en) * | 2007-09-26 | 2009-04-02 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
KR101108450B1 (ko) * | 2007-11-20 | 2012-02-20 | 아사히 가세이 겐자이 가부시키가이샤 | 열경화성 수지 발포판의 제조 방법 |
KR20100126361A (ko) | 2008-02-08 | 2010-12-01 | 에일러론 테라퓨틱스 인코포레이티드 | 치료용 펩티드유사 거대고리 |
EP2310407A4 (en) | 2008-04-08 | 2011-09-14 | Aileron Therapeutics Inc | BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES |
WO2010034034A1 (en) | 2008-09-22 | 2010-03-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
EP2352507A4 (en) | 2008-11-24 | 2012-04-25 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES |
CA2777700A1 (en) * | 2009-10-14 | 2011-04-21 | Aileron Therapeutics, Inc. | Improved peptidomimetic macrocycles |
-
2009
- 2009-02-09 KR KR1020107020028A patent/KR20100126361A/ko active Search and Examination
- 2009-02-09 CN CN200980108027XA patent/CN101980718A/zh active Pending
- 2009-02-09 US US12/378,047 patent/US20090275519A1/en not_active Abandoned
- 2009-02-09 WO PCT/US2009/000837 patent/WO2009099677A2/en active Application Filing
- 2009-02-09 EP EP15153712.3A patent/EP2926827A3/en not_active Withdrawn
- 2009-02-09 CA CA2714251A patent/CA2714251C/en not_active Expired - Fee Related
- 2009-02-09 BR BRPI0907754-5A patent/BRPI0907754A2/pt not_active Application Discontinuation
- 2009-02-09 JP JP2010545895A patent/JP2011511076A/ja active Pending
- 2009-02-09 DE DE112009000300T patent/DE112009000300T5/de not_active Withdrawn
- 2009-02-09 CN CN201410541607.0A patent/CN104474529A/zh active Pending
- 2009-02-09 EP EP09707916A patent/EP2242503A4/en not_active Withdrawn
- 2009-02-09 GB GB1014734A patent/GB2471588A/en not_active Withdrawn
-
2010
- 2010-08-04 IL IL207421A patent/IL207421A0/en active IP Right Grant
- 2010-08-11 ZA ZA2010/05741A patent/ZA201005741B/en unknown
-
2012
- 2012-01-17 US US13/352,223 patent/US8808694B2/en not_active Expired - Fee Related
-
2014
- 2014-07-08 US US14/325,933 patent/US20150038430A1/en not_active Abandoned
- 2014-12-02 JP JP2014244169A patent/JP2015078208A/ja active Pending
-
2015
- 2015-12-20 IL IL243240A patent/IL243240A/en active IP Right Grant
-
2018
- 2018-06-29 US US16/023,606 patent/US20190071469A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011511076A5 (ja) | ||
NZ605420A (en) | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway | |
NZ602824A (en) | Sparc binding peptides and uses thereof | |
PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
MX336412B (es) | Nuevos analogos de glucagon. | |
JP2015520184A5 (ja) | ||
NZ611620A (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
JP2017523184A5 (ja) | ||
EP2562183A8 (en) | Novel immunogenic epitopes for immunotherapy | |
JP2016506935A5 (ja) | ||
NZ598085A (en) | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid | |
JP2011528333A5 (ja) | ||
NZ604089A (en) | Multivalent glycopeptide constructs and uses thereof | |
JP2010509932A5 (ja) | ||
JP2014528901A5 (ja) | ||
NZ599670A (en) | Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers | |
JP2017524733A5 (ja) | ||
JP2011225596A5 (ja) | ||
JP2014513952A5 (ja) | ||
JP2013520986A5 (ja) | ||
RU2013122898A (ru) | Похоксимовые конъюгаты, применимые для лечения связанных с hsp90 патологий, композиция и способ лечения с их помощью | |
JP2018522880A5 (ja) | ||
RU2015119523A (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
JP2016516005A5 (ja) | ||
RU2013111675A (ru) | Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc |